[Swedish polio-protection is satisfactory. But before the disease is eradicated, everybody should be vaccinated].

M. Böttiger,O. Gustavsson,A. Svensson

1996-01-17

Abstract:

What problem does this paper attempt to address?

Enhanced cellular immune response in women with PTSD related to childhood abuse.

M. Altemus,M. Cloitre,F. Dhabhar

DOI: https://doi.org/10.1176/APPI.AJP.160.9.1705

IF: 17.7

2003-09-01

American Journal of Psychiatry

Abstract:OBJECTIVE Disturbed regulation of both the hypothalamic-pituitary-adrenal (HPA) axis and the sympathoadrenomedullary system in posttraumatic stress disorder (PTSD) suggests that immune function, which is modulated by these systems, also may be dysregulated in individuals with PTSD. METHOD Delayed-type hypersensitivity skin test responses were measured in 16 women with PTSD due to childhood sexual or physical abuse and 15 women who did not have a history of abuse, other trauma, or psychiatric disorders. HPA axis activity was assessed by examination of circadian salivary cortisol levels and a single time point measurement of plasma cortisol. RESULTS Delayed-type hypersensitivity was enhanced in women with PTSD. Cortisol measures did not differ between PTSD and healthy comparison subjects. CONCLUSIONS These results suggest that cell-mediated inflammatory reactions are greater in individuals with PTSD.
Abnormalities Of The Bone Marrow Immune Microenvironment In Patients With Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

Yang Song,Yuan Kong,Min-Min Shi,Yu-Qian Sun,Yu Wang,Xiao-Hui Zhang,Lan-Ping Xu,Xiao-Jun Huang

DOI: https://doi.org/10.1182/blood.V128.22.4602.4602

IF: 20.3

2016-01-01

Blood

Abstract:Prolonged isolated thrombocytopenia (PT) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Whether abnormalities of the bone marrow (BM) immune microenvironment are involved in the pathogenesis of PT remains unknown, however. Twenty patients with PT, 40 matched patients with good graft function (GGF) after allo-HSCT, and 20 healthy donors (HD) were enrolled in this nested case-control study. Th1, Th2, Tc1, Tc2, Th17, and Treg cells were analyzed by flow cytometry, and IFN-γ, IL-4, IL-17, IL-6, IL-21, and thrombopoietin levels in BM plasma were evaluated with a cytometric bead assay and ELISA. Relative to GGF patients and HD controls, PT patients had significantly higher proportions of Th1 and Tc1 cells, resulting in higher Th1/Th2 and Tc1/Tc2 ratios in the BM microenvironment. In addition, the excessive polarization of Th17 was observed in patients with PT. Changes in BM plasma cytokines were consistent with our cellular findings. These results suggest that dysregulated T cell responses in the BM microenvironment might play an important role in the pathogenesis of PT.
Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia

G. Grazzini,V. Agostini,G. Forni,L. Omert,J. Boudreaux

DOI: https://doi.org/10.3389/frhem.2023.1187681

2023-06-20

Abstract:Beta thalassemia (β-thalassemia) is part of a group of inherited hemoglobinopathies caused by a mutation in the beta globin gene, leading to minimal functional hemoglobin and resulting in damaged red blood cells and anemia. β-Thalassemia is most common in the Mediterranean region, South-East Asia, the Indian subcontinent, and the Middle East. Many of these regions include low- and middle-income countries where there are significant unmet needs in the adequate care and management of thalassemia. Patients with transfusion-dependent β-thalassemia, the most severe form of the disease, require regular blood transfusions. Chronic transfusions are often accompanied by iron chelation therapy to manage ferritin levels. Complications caused by transfusions and iron overload are only partially addressed by current treatment strategies, which negatively affect the quality of life of patients with transfusion-dependent β-thalassemia. Until curative modalities become available for all patients worldwide, methods of optimizing supportive treatments are needed to reduce the symptoms of ineffective erythropoiesis; minimize transfusion-related reactions and side effects; reduce rates of alloimmunization and transfusion-transmitted infections; and to reduce the psychosocial burden on both patients and their caregivers. This review aims to provide an overview and comparison of the ways transfusion-dependent β-thalassemia is identified and treated in different geographic regions, to assess unmet needs specific to these regions, and to discuss how therapies currently in development may improve care.

Medicine
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Irene Motta,Rayan Bou-Fakhredin,Ali T. Taher,Maria Domenica Cappellini

DOI: https://doi.org/10.1007/s40265-020-01341-9

2020-06-15

Drugs

Abstract:Hemoglobinopathies are among the most common monogenic diseases worldwide. Approximately 1–5% of the global population are carriers for a genetic thalassemia mutation. The thalassemias are characterized by autosomal recessive inherited defects in the production of hemoglobin. They are highly prevalent in the Mediterranean, Middle East, Indian subcontinent, and East and Southeast Asia. Due to recent migrations, however, the thalassemias are now becoming more common in Europe and North America, making this disease a global health concern. Currently available conventional therapies in thalassemia have many challenges and limitations. A better understanding of the pathophysiology of β-thalassemia in addition to key developments in optimizing transfusion programs and iron-chelation therapy has led to an increase in the life span of thalassemia patients and paved the way for new therapeutic strategies. These can be classified into three categories based on their efforts to address different features of the underlying pathophysiology of β-thalassemia: correction of the globin chain imbalance, addressing ineffective erythropoiesis, and improving iron overload. In this review, we provide an overview of the novel therapeutic approaches that are currently in development for β-thalassemia.

pharmacology & pharmacy,toxicology
Structural defects of T-even bacteriophages.

Donald J. Cummings,N. Couse,Gerald L. Forrest

DOI: https://doi.org/10.1016/S0065-3527(08)60020-2

Advances in Virus Research

Abstract:
Bone disease in β thalassemia patients: past, present and future perspectives

Vincenzo De Sanctis,Ashraf T Soliman,Heba Elsefdy,Nada Soliman,Elsaid Bedair,Bernadette Fiscina,Christos Kattamis

DOI: https://doi.org/10.1016/j.metabol.2017.09.012

IF: 13.934

Metabolism

Abstract:Bone disorders in patients with thalassemia major (TM) and intermedia (TI) constitute complex conditions that result from various factors affecting the growing skeleton. Although much progress has been made in our understanding of the natural history, pathogenesis and clinical manifestations of β- and δβ-thalassemia, bone manifestations remain a puzzle for the clinician. In this review, we outline the key points in the current literature on the pathogenesis and management of bone disease in patients with TM and TI who were conventionally treated in recent decades with frequent blood transfusions and iron chelation. Prevention, early recognition and treatment are the most effective strategies for the management of bone disease in these patients. However, further studies are required to maintain optimal bone health for both TM and TI patients. Studying bone disease in patients with non-transfusion dependent TI, which seems to worsen considerably with age, is important to delineate the effect of the disease itself on bone health without the intervening factors of transfusions, iron intoxication and chelation.
Iron overload: the Achilles heel of β- thalassemia

Efthymia Vlachaki,Theodora-Maria Venou

DOI: https://doi.org/10.1016/j.tracli.2024.06.001

IF: 2.126

2024-06-08

Transfusion Clinique et Biologique

Abstract:Systematic transfusions coupled with iron chelation therapy have substantially improved the life expectancy of thalassemia patients in developed nations. As the human organism does not have a protective mechanism to remove excess iron, iron overload is a significant concern in thalassemia, leading to organ damage, especially in the heart and liver. Thus, iron chelation therapy is crucial to prevent or reverse organ iron overload. There are three widely used iron chelators, either as monotherapy or in combination. The choice of iron chelator depends on several factors, including local guidelines, drug availability, and the individual clinical scenario. Despite treatment advancements, challenges persist, especially in resource-limited settings, highlighting the need for improved global healthcare access. This review discusses clinical management, current treatments, and future directions for thalassemia, focusing on iron overload and its complications. Furthermore, it underscores the progress in transforming thalassemia into a manageable chronic condition and the potential of novel therapies to further enhance patient outcomes.

immunology,hematology
A Review of Iron Overload in Beta-Thalassemia Major, and a Discussion on Alternative Potent Iron Chelation Targets

P. Yadav,Ashutosh Kumar Singh

DOI: https://doi.org/10.1177/26348535221103560

2022-01-01

Abstract:For years, arrhythmias have been well documented in the medical arena as a cardiovascular consequence of iron overload (IO). They are thought to be linked to the accumulation of iron in the myocardium. Iron is the earth's fourth most abundant element and the second most plentiful metal (after aluminium). When it comes to biology, iron fills two roles: it's necessary and it's poisonous. It is necessary as a trace iron element since it is found in hemoproteins such as haemo-globin, but it is poisonous in excess amounts of the ability to produce free radicals, which can harm the biological system. The high prevalence of cardiomyopathy in patients with hemosiderosis, particularly in cases of transfusional iron overload, strongly suggests that iron deposition in the heart plays a key role in the development of heart failure. Thalassemia major, which necessitates blood transfusion as a treatment, absorbs a large amount of iron in the patient's duodenum. Moreover, Iron Overload causes a threat to vital organs such as the liver and, initiates events of the pathologic progression involving apoptosis, fibrosis, and ultimately cardiac dysfunction. Furthermore, we discuss the iron overload issue as it relates to beta-thalassemia major patient blood transfusion treatment, as well as key individuals accountable for iron excess that ultimately leads to cardiomyopathy.

Medicine
[Research progress of iron metabolism in phenotype modification of β-thalassemia]

Diyu Chen,Xiaofang Sun

DOI: https://doi.org/10.3760/cma.j.cn511374-20190819-00418

2021-01-10

Abstract:β-thalassemia is a type of inherited hemolytic anemia caused by decreased globin production due to defect of the HBB gene. The pathogenesis of the disease is imbalance of α/β globin chains. The excess of α-globin chains will form hemichromes which can damage red blood cell membranes and lead to hemolysis, ineffective erythropoiesis, and secondary iron overload. Iron overload in turn can cause complications such as growth retardation, liver cirrhosis, cardiac insufficiency, and aggravate the disease phenotype. In recent decades, genes participating in iron metabolism have been discovered, and the mechanism of iron metabolism in the development of thalassemia has gradually been elucidated. Subsequently, by manipulating the expression of key genes in iron metabolism such as hepcidin and transferrin receptor, researchers have revealed that iron restriction can improve ineffective hematopoiesis and iron overload, which may provide a potential approach for the treatment of thalassemia. This article reviews the progress of research on iron metabolism-related genes and related pathways in β-thalassemia.
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

Valeria Maria Pinto,Gian Luca Forni

DOI: https://doi.org/10.3390/ijms21228771

2020-11-20

Abstract:Thalassemia syndromes are characterized by the inability to produce normal hemoglobin. Ineffective erythropoiesis and red cell transfusions are sources of excess iron that the human organism is unable to remove. Iron that is not saturated by transferrin is a toxic agent that, in transfusion-dependent patients, leads to death from iron-induced cardiomyopathy in the second decade of life. The availability of effective iron chelators, advances in the understanding of the mechanism of iron toxicity and overloading, and the availability of noninvasive methods to monitor iron loading and unloading in the liver, heart, and pancreas have all significantly increased the survival of patients with thalassemia. Prolonged exposure to iron toxicity is involved in the development of endocrinopathy, osteoporosis, cirrhosis, renal failure, and malignant transformation. Now that survival has been dramatically improved, the challenge of iron chelation therapy is to prevent complications. The time has come to consider that the primary goal of chelation therapy is to avoid 24-h exposure to toxic iron and maintain body iron levels within the normal range, avoiding possible chelation-related damage. It is very important to minimize irreversible organ damage to prevent malignant transformation before complications set in and make patients ineligible for current and future curative therapies. In this clinical case-based review, we highlight particular aspects of the management of iron overload in patients with beta-thalassemia syndromes, focusing on our own experience in treating such patients. We review the pathophysiology of iron overload and the different ways to assess, quantify, and monitor it. We also discuss chelation strategies that can be used with currently available chelators, balancing the need to keep non-transferrin-bound iron levels to a minimum (zero) 24 h a day, 7 days a week and the risk of over-chelation.
[Overview of new approaches to β-thalassemia treatment]

Xian-Feng Guo,Lu Han,Xu-Chao Zhang,Hai-Hang Zhang,Jing Liu

2024-06-25

Abstract:Hemoglobinopathies are one of the most common single-gene genetic disorders globally, with approximately 1% to 5% of the global population carrying the mutated gene for thalassemia. Thalassemia are classified into transfusion-dependent thalassemia and non-transfusion-dependent thalassemia based on the need for blood transfusion. Traditional treatment modalities include blood transfusion, splenectomy, hydroxyurea therapy, and iron chelation therapy, which are now widely used for clinical treatment and constitute the main methods recommended in the β-thalassemia treatment guidelines. However, there are multiple barriers and limitations to the application of these approaches, and there is an urgent need to explore new therapeutic approaches. With the in-depth study of the pathophysiological process of β-thalassemia, a deeper understanding of the pathogenesis of the disease has been gained. It has been demonstrated that the pathogenesis of thalassemia is closely related to ineffective erythropoiesis (IE), imbalance in the ratio of α/β-globin protein chains and iron overload. New therapeutic approaches are emerging for different pathogenic mechanisms. Among them, new drugs for the treatment of IE mainly include activin receptor II trap ligands, Janus kinase 2 inhibitors, pyruvate kinase activators, and glycine transporter protein 1 inhibitors. Correcting the imbalance in the hemoglobin chain is mainly due to emerging technologies such as bone marrow transplantation and gene editing. Measures in reducing iron overload are associated with inhibiting the activity of transferrin and hepcidin. These new approaches provide new ideas and options for the treatment and management of β-thalassemia.
The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia

Siyang Lin,Yanping Zheng,Meihuan Chen,Liangpu Xu,Hailong Huang

DOI: https://doi.org/10.3389/fphys.2024.1346173

IF: 4

2024-02-26

Frontiers in Physiology

Abstract:In Guangxi, Hainan, and Fujian Province in southern China, β-thalassemia is a frequent monogenic hereditary disorder that is primarily defined by hemolytic anemia brought on by inefficient erythropoiesis. It has been found that ineffective erythropoiesis in β-thalassemia is closely associated with a high accumulation of Reactive oxygen species, a product of oxidative stress, in erythroid cells. During recent years, ferroptosis is an iron-dependent lipid peroxidation that involves abnormalities in lipid and iron metabolism as well as reactive oxygen species homeostasis. It is a recently identified kind of programmed cell death. β-thalassemia patients experience increased iron release from reticuloendothelial cells and intestinal absorption of iron, ultimately resulting in iron overload. Additionally, the secretion of Hepcidin is inhibited in these patients. What counts is both ineffective erythropoiesis and ferroptosis in β-thalassemia are intricately linked to the iron metabolism and Reactive oxygen species homeostasis. Consequently, to shed further light on the pathophysiology of β-thalassemia and propose fresh ideas for its therapy, this paper reviews ferroptosis, ineffective erythropoiesis, and the way they interact.

physiology
Established Approaches, Old Issues, New Non-Curative Therapies, and Perspectives on Healing

Raffaella Origa,Layal Issa

DOI: https://doi.org/10.3390/jcm13226966

IF: 3.9

2024-11-27

Journal of Clinical Medicine

Abstract:Despite a decrease in prevalence and incidence rates, beta thalassemia continues to represent a significant public health challenge worldwide. In high-resource settings, children with thalassemia have an open prognosis, with a high chance of reaching adulthood and old age with a good quality of life. This is achievable if transfusion therapy is properly managed, effectively mitigating ineffective erythropoiesis and its associated complications while also minimizing excessive iron accumulation. Adequate iron chelation is essential to maintain reactive forms of iron within the normal range throughout life, thus preventing organ damage caused by hemosiderosis, which inevitably results from a regular transfusion regimen. New therapies, both curative, such as gene therapy, and non-curative, such as modulators of erythropoiesis, are becoming available for patients with transfusion-dependent beta thalassemia. Two curative approaches based on gene therapy have been investigated in both adults and children with thalassemia. The first approach uses a lentivirus to correct the genetic defect, delivering a functional gene copy to the patient's cells. The second approach employs CRISPR/Cas9 gene editing to directly modify the defective gene at the molecular level. No non-curative therapies have received approval for pediatric use. Among adults, the only available drug is luspatercept, which is currently undergoing clinical trials in pediatric populations. However, in many countries around the world, the new therapeutic options remain a mirage, and even transfusion therapy itself is not guaranteed for most patients, while the choice of iron chelation therapy depends on drug availability and affordability.

medicine, general & internal
Endocrinopathies in beta thalassemia: a narrative review

Theodora-Maria Venou,Fani Barmpageorgopoulou,Melpomeni Peppa,Efthimia Vlachaki

DOI: https://doi.org/10.1007/s42000-023-00515-w

Abstract:Beta thalassemia is the most common genetic blood disorder, characterized by reduced production or complete absence of beta-globin chains. The combination of systematic red blood cell transfusion and iron chelation therapy is the most readily available supportive treatment and one that has considerably prolonged the survival of thalassemia patients. Despite this, the development of endocrine abnormalities correlated with beta thalassemia still exists and is mostly associated with iron overload, chronic anemia, and hypoxia. A multifactorial approach has been employed to investigate other factors involved in the pathogenesis of endocrinopathies, including genotype, liver disease, HCV, splenectomy, socioeconomic factors, chelation therapy, and deficiency of elements. The development of specific biomarkers for predicting endocrinopathy risk has been the subject of extensive discussion. The objective of the present narrative review is to present recent data on endocrinopathies in beta thalassemia patients, including the prevalence, the proposed pathogenetic mechanisms, the risk factors, the diagnostic methods applied, and finally the recommended treatment options.
PD02 A Literature Review Of Treatment Schemes And Effects For Beta Thalassemia In China

Jiaqi Yuan,Jingyi Qiao,Junling Weng,Bingxing Luo,Juntao Yan,Jian Ming,Yingyao Chen

DOI: https://doi.org/10.1017/s0266462322002677

2022-01-01

International Journal of Technology Assessment in Health Care

Abstract:IntroductionThe incidence of beta thalassemia varies greatly in different regions of China. Blood transfusion combined with iron chelation and hematopoietic stem cell transplantation (HSCT) is the main treatment for beta thalassemia in China. This study aimed to reveal the specific treatment schemes used for patients with beta thalassemia and to evaluate their effects.MethodsA search strategy was developed to identify articles published between 1 January 2010 and 30 August 2021 in the following literature databases: PubMed, Embase, the China National Knowledge Infrastructure, Wanfang Data, and the Chinese BioMedical Literature Database.ResultsThe most used iron chelation schemes in China for patients with beta thalassemia included deferoxamine (DFO) monotherapy, deferiprone (DFP) monotherapy, deferasirox (DFX) monotherapy, and combinations of DFP and DFO. Most studies reported that combinations of DFP, DFO, and DFX monotherapy performed better than DFO or DFP monotherapy alone in reducing the blood, heart, and liver iron load. However, the adverse effects of iron chelation affected patient compliance with treatment to a certain extent. Stem cells for patients receiving HSCT in China were mainly donated by human leukocyte antigen (HLA)-matched siblings or unrelated individuals. The five-year overall survival rate after HSCT ranged from 83 to 90 percent, while the five-year beta thalassemia-free survival rate ranged from 65 to 87 percent. Graft-versus-host disease and infection were the most common serious complications experienced by transplant recipients.ConclusionsFor patients in China with beta thalassemia, the most effective iron chelation treatment schemes were combinations of DFP, DFO, and DFX monotherapy. HSCT from HLA-matched siblings or unrelated donors resulted in a significant improvement in the cure rate for beta thalassemia. However, patients still need safer and more effective innovative treatments, and further evidence on existing treatments needs to be generated from larger scale studies in the Chinese population.
Current status of beta‐thalassemia and its treatment strategies

Shaukat Ali,Shumaila Mumtaz,Hafiz Abdullah Shakir,Muhammad Khan,Hafiz Muhammad Tahir,Samaira Mumtaz,Tafail Akbar Mughal,Ali Hassan,Syed Akif Raza Kazmi,Sadia,Muhammad Irfan,Muhammad Adeeb Khan

DOI: https://doi.org/10.1002/mgg3.1788

2021-11-05

Abstract:BACKGROUND: Thalassemia is an inherited hematological disorder categorized by a decrease or absence of one or more of the globin chains synthesis. Beta-thalassemia is caused by one or more mutations in the beta-globin gene. The absence or reduced amount of beta-globin chains causes ineffective erythropoiesis which leads to anemia.METHODS: Beta-thalassemia has been further divided into three main forms: thalassemia major, intermedia, and minor/silent carrier. A more severe form among these is thalassemia major in which individuals depend upon blood transfusion for survival. The high level of iron deposition occurs due to regular blood transfusion therapy.RESULTS: Overloaded iron raises the synthesis of reactive oxygen species (ROS) that are noxious and prompting the injury to the hepatic, endocrine, and vascular system. Thalassemia can be analyzed and diagnosed via prenatal testing (genetic testing of amniotic fluid), blood smear, complete blood count, and DNA analysis (genetic testing). Treatment of thalassemia intermediate is symptomatic; however; it can also be accomplished by folic supplementation and splenectomy.CONCLUSION: Thalassemia major can be cured through regular transfusion of blood, transplantation of bone marrow, iron chelation management, hematopoietic stem cell transplantation, stimulation of fetal hemoglobin production, and gene therapy.

genetics & heredity
Efficacy and safety of thalidomide in patients with β-thalassemia intermedia and major

Wendong Ju,Gaomin Din,Jun Huang,Minmin Zheng,Xiaoyou Wang,Lingling Liu,Li Wang,Suling Xuan,Weiqun Xiao,Ang Chen

DOI: https://doi.org/10.1097/md.0000000000040328

IF: 1.6

2024-10-30

Medicine

Abstract:β-Thalassemia is 1 of the most common monogenic hereditary blood disorders worldwide. It is caused by mutations in the Hb β-chain gene, characterized by reduced or absent β-globin synthesis, ineffective erythropoiesis, and relative excess of α-chains. [ 1 ] The excess α-chains aggregate to form inclusions, compromising red cell membrane integrity and leading to hemolysis. Clinical manifestations include hemolytic anemia, hepatosplenomegaly, skeletal deformities, and in severe cases, life-threatening complications. Based on the severity of clinical symptoms, β-thalassemia is classified into severe thalassemia major (TM), thalassemia intermedia (TI), mild thalassemia, and carriers. Additionally, according to transfusion requirements, β-thalassemia is categorized as transfusion-dependent thalassemia (TDT) or non-TDT (NTDT). [ 2 ] TI is a type of NTDT, while TM is a type of TDT. [ 3 ]

medicine, general & internal
Single-cell profiling of ineffective erythropoiesis in a mouse model of β-thalassaemia intermedia

Yuanliang Peng,Long Liang,Haihang Zhang,Hong Liu,Guanxiong Zhang,Shuming Sun,Xianfeng Guo,Yanpeng Wang,Bin Hu,Rui Liu,Yanan Li,Ling Nie,Ji Zhang,Mao Ye,Yelena Z Ginzburg,Zhong Lin,Biao Yin,Huiyong Chen,Jing Liu

DOI: https://doi.org/10.1111/bjh.18706

Abstract:Beta-thalassaemia is an inherited haemoglobin disorder characterised by ineffective erythropoiesis (IE). The detailed pathogenesis of IE remains unclear. In this study, we used single-cell RNA sequencing (scRNA-seq) to examine IE in Th3/+ β-thalassaemic mice. The results showed that the erythroid group was remarkably expanded, and genes involved in biological processes such as iron metabolism, haeme synthesis, protein folding, and response to heat were significantly upregulated from erythroid progenitors to reticulocytes in β-thalassaemic mice. In particular, we identified a unique cell population close to reticulocytes, named ThReticulocytes, characterised by a high level of heat shock protein 70 (Hsp70) expression and dysregulation of iron metabolism and haeme synthesis signalling. Treatment of β-thalassaemic mice with the haeme oxygenase inhibitor tin-mesoporphyrin effectively improved the iron disorder and IE, and the ThReticulocyte population and Hsp70 expression were significantly suppressed. This study revealed in detail the progression of IE at the single-cell level and possibly provided clues to find therapeutic targets in thalassaemia.
β-Thalassemia gene editing therapy: Advancements and difficulties

Jing Hu,Yebing Zhong,Pengxiang Xu,Liuyan Xin,Xiaodan Zhu,Xinghui Jiang,Weifang Gao,Bin Yang,Yijian Chen

DOI: https://doi.org/10.1097/md.0000000000038036

IF: 1.6

2024-05-05

Medicine

Abstract:β-Thalassemia is an inherited disorder of hemoglobin (Hb) production, resulting in ineffective erythropoiesis. [ 1 ] Chronic hemolysis is the predominant symptom, with clinical signs of myeloproliferative, extramedullary hematopoiesis, and iron homeostasis disorders. [ 1 ] Patients with thalassemia suffer from the most common monogenic hereditary disease worldwide and also represent the largest monogenic hereditary disease in China. [ 2 ] It originates from the Mediterranean, the Middle East, and Southeast Asia. The disease has a widespread distribution among populations and affects a large number of individuals, with an estimated carrier rate of the β-thalassemia gene at around 1.5% globally. [ 3 ] β-Thalassemia is classified as nontransfusion dependent β-thalassemia or transfusion-dependent β-thalassemia (TDT) on the basis of transfusion requirements. [ 4 ] Regular transfusion is the mainstay of treatment for patients with TDT; however, it brings with it iron loading related to transfusion, increased irreversible end-organ toxicity, and adverse effects of iron chelators. Hematopoietic stem cell transplantation is the only treatment, and gene editing therapy has opened the door to a cure for β-thalassemia patients. In recent years, gene editing has been developed rapidly and applied widely, such as applying mature gene-addition technology, directly repairing defective β-pearl protein genes on autologous HSCs such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and especially the emerging CRISPR-Cas9 genome editing technology, or activating other genes that can replace the function of β-pearl proteins. Here, we review the emerging gene therapy modalities for the treatment of thalassemia and the possibilities for future directions.

medicine, general & internal
Revisiting beta thalassemia intermedia: past, present, and future prospects

Naouel Ben Salah,Rayan Bou-Fakhredin,Fethi Mellouli,Ali T. Taher

DOI: https://doi.org/10.1080/10245332.2017.1333246

IF: 2.264

2017-06-07

Hematology

Abstract:BACKGROUND: The spectrum of thalassemias is wide ranging from thalassemia minor, which consists of mild hypochromic microcytic anemia without obvious clinical manifestations, to thalassemia major (TM), which is characterized by severe anemia since the first years of life and is transfusion dependent. Thalassemia intermedia (TI) describes those patients with mild or moderate anemia.OBJECTIVE: To describe the genetic features and major clinical complications of TI, and the therapeutic approaches available in the management of this disease.METHODS: Publications from potentially relevant journals were searched on Medline.RESULTS AND DISCUSSION: Over the past decade, the understanding of TI has increased with regard to pathophysiology and molecular studies. It is now clear that clinical presentation and specific complications make TI different from TM. It is associated with greater morbidity, a wider spectrum of organ dysfunction and more complications than previously thought.CONCLUSION: TI is not a mild disease. The interplay of three hallmark pathophysiologic factors (ineffective erythropoiesis, chronic anemia, and iron overload) leads to the clinical presentations seen in TI. New treatment modalities are currently being investigated to broaden the options available for TI management.

hematology

[Swedish polio-protection is satisfactory. But before the disease is eradicated, everybody should be vaccinated].

Enhanced cellular immune response in women with PTSD related to childhood abuse.

Abnormalities Of The Bone Marrow Immune Microenvironment In Patients With Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Structural defects of T-even bacteriophages.

Bone disease in β thalassemia patients: past, present and future perspectives

Iron overload: the Achilles heel of β- thalassemia

A Review of Iron Overload in Beta-Thalassemia Major, and a Discussion on Alternative Potent Iron Chelation Targets

[Research progress of iron metabolism in phenotype modification of β-thalassemia]

Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

[Overview of new approaches to β-thalassemia treatment]

The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia

Established Approaches, Old Issues, New Non-Curative Therapies, and Perspectives on Healing

Endocrinopathies in beta thalassemia: a narrative review

PD02 A Literature Review Of Treatment Schemes And Effects For Beta Thalassemia In China

Current status of beta‐thalassemia and its treatment strategies

Efficacy and safety of thalidomide in patients with β-thalassemia intermedia and major

Single-cell profiling of ineffective erythropoiesis in a mouse model of β-thalassaemia intermedia

β-Thalassemia gene editing therapy: Advancements and difficulties

Revisiting beta thalassemia intermedia: past, present, and future prospects